Retrospective Analysis of Peripheral Blood Stem Cell Transplantationfor the Treatment of High-Risk Neuroblastoma

• Published in: Journal of Korean medical science pp. 66 - 72
• Main Authors: Eun Kyung Kim, 강형진, Jeong Ah Park, 최형수, 신희영, 안효섭
• Format: Journal Article
• Language: English
• Published: 대한의학회 01.09.2007
• Subjects: 의학일반
• ISSN: 1011-8934; 1598-6357

Disease relapse after autologous peripheral blood stem cell transplantation (APBSCT) is the main cause of treatment failure in high-risk neuroblastoma (NBL). To reduce relapse, various efforts have been made such as CD34+ selection and double APBSCT. Here the authors reviewed the clinical features and outcomes of highrisk NBL patients and analyzed their survival. The medical records of 36 patients with stage III or IV NBL who underwent APBSCT at Seoul National University Children’s Hospital between May 1996 and May 2004 were reviewed. Total 46 APBSCTs were performed in 36 patients. Disease free survival (DFS) and overall survival of all patients were 47.7% and 68.8%, respectively. The patients were allocated to three groups according to the APBSCT type. The DFS of CD34+ non-selected single APBSCT patients (N=13), CD34+ selected single APBSCT patients (N= 14), and CD34+ selected double APBSCT patients (N=9) were 55.6%, 40.6%, and 50.0%, respectively, which were not significantly different. Thus the survival was not found to be affected by CD34+ selection or transplantation number. To improve long-term survival, various efforts should be made such as chemotherapy dose intensification, more effective tumor purging, and control of minimal residual disease via the use of differentiating and immune-modulating agents. KCI Citation Count: 4